35771-41-6

Basic information

• Product Name: 3-Pyridinol, 6-[(4-nitrophenyl)azo]-
• CAS NO: 35771-41-6
• Molecular Formula: C11H8N4O3
• Molecular Weight: 244.21
• Mol File: 35771-41-6.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 3-Pyridinol, 6-[(4-nitrophenyl)azo]-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinol, 6-[(4-nitrophenyl)azo]-(35771-41-6)
• EPA Substance Registry System: 3-Pyridinol, 6-[(4-nitrophenyl)azo]-(35771-41-6)

Safety Data

• Hazardous Substances Data: 35771-41-6(Hazardous Substances Data)

Upstream product

• 109-00-2 3-HYDROXYPYRIDINE 
• 100-01-6 4-nitro-aniline 

Downstream Products

• 69634-17-9 N-(5-hydroxy-pyridin-2-yl)benzamide 
• 121991-47-7 N-(5-benzoyloxy-[2]pyridyl)-dibenzamide 
• 159183-89-8 2-acetamido-5-hydroxypyridine 
• 329280-06-0 2-[2-(4-nitrophenyl)diazenyl]-5-(2,3-epoxy-propoxy)pyridine 
• 108477-12-9 2-benzoylamino-5-benzoyloxy-pyridine 
• 89943-11-3 2-amino-5-ethoxypyridine 
• 55717-46-9 6-aminopyridin-3-ol 
• 110861-14-8 5-(difluoromethoxy)pyridine-2-amine 
• 110860-91-8 [5-(2-Chloro-1,1,2-trifluoro-ethoxy)-pyridin-2-yl]-(4-nitro-phenyl)-diazene 
• 110861-10-4 (4-Nitro-phenyl)-[5-(1,1,2,2-tetrafluoro-ethoxy)-pyridin-2-yl]-diazene 
• 110861-12-6 (5-Difluoromethoxy-pyridin-2-yl)-(4-nitro-phenyl)-diazene 
• 110861-11-5 [5-(1,1,2,3,3,3-Hexafluoro-propoxy)-pyridin-2-yl]-(4-nitro-phenyl)-diazene 

Relevant articles and documents

Novel pyridine bioisostere of cabozantinib as a potent c-met kinase inhibitor: Synthesis and anti-tumor activity against hepatocellular carcinoma

Two novel bioisosteres of cabozantinib, 3 and 4, were designed and synthesized. The ben-zene ring in the center of the cabozantinib structure was replaced by trimethylpyridine (3) and pyridine (4), respectively. Surprisingly, the two compounds showed extremely contrasting mesenchy-mal–epithelial transition factor (c-Met) inhibitory activities at 1 μM concentration (4% inhibition of 3 vs. 94% inhibition of 4). The IC50 value of compound 4 was 4.9 nM, similar to that of cabozantinib (5.4 nM). A ligand-based docking study suggested that 4 includes the preferred conformation for the binding to c-Met in the conformational ensemble, but 3 does not. The anti-proliferative activity of compound 4 against hepatocellular carcinoma (Hep3B and Huh7) and non-small-cell lung cancer (A549 and H1299) cell lines was better than that of cabozantinib, whereas 3 did not show a signifi-cant anti-proliferative activity. Moreover, the tumor selectivity of compound 4 toward hepatocellu-lar carcinoma cell lines was higher than that of cabozantinib. In the xenograft chick tumor model, compound 4 inhibited Hep3B tumor growth to a much greater extent than cabozantinib. The present study suggests that compound 4 may be a good therapeutic candidate against hepatocellular carci-noma.